Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020)

Historic Long-Term Deferred Tax for Celldex Therapeutics (CLDX) over the last 2 years, with Q4 2020 value amounting to $297.3 million.

  • Celldex Therapeutics' Long-Term Deferred Tax fell 94.05% to $297.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $297.3 million, marking a year-over-year decrease of 94.05%. This contributed to the annual value of $297.3 million for FY2020, which is 94.05% down from last year.
  • Celldex Therapeutics' Long-Term Deferred Tax amounted to $297.3 million in Q4 2020, which was down 94.05% from $300.2 million recorded in Q4 2019.
  • Celldex Therapeutics' 5-year Long-Term Deferred Tax high stood at $300.2 million for Q4 2019, and its period low was $297.3 million during Q4 2020.